Literature DB >> 27759173

Thiomaltol-Based Organometallic Complexes with 1-Methylimidazole as Leaving Group: Synthesis, Stability, and Biological Behavior.

Carmen M Hackl1, Maria S Legina1, Verena Pichler1, Melanie Schmidlehner1, Alexander Roller1, Orsolya Dömötör2,3, Eva A Enyedy2, Michael A Jakupec1,4, Wolfgang Kandioller1,4, Bernhard K Keppler1,4.   

Abstract

Thiomaltol, a potential S,O-coordinating molecule, has been utilized for the complexation of four different organometallic fragments, yielding the desired RuII , OsII , RhIII , and IrIII complexes having a "piano-stool" configuration. In addition to the synthesis of these compounds with a chlorido leaving group, the analogous 1-methylimidazole derivatives have been prepared, giving rise to thiomaltol-based organometallics with enhanced stability under physiological conditions. The organometallic compounds have been characterized by NMR spectroscopy, elemental analysis, and X-ray diffraction analysis. Their behavior in aqueous solution and their interactions with certain amino acids have been studied by ESI mass spectrometry. Their pH-dependent stability has been investigated by 1 H NMR in aqueous solution, and their cytotoxicity against three different cancer cell lines has been investigated. Furthermore, their capacity as topoisomerase IIα inhibitors as well as their effect on the cell cycle distribution and reactive oxygen species (ROS) generation have been elucidated.
© 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  antitumor agents; leaving group variation; medicinal chemistry; organometallics; thiomaltol

Mesh:

Substances:

Year:  2016        PMID: 27759173     DOI: 10.1002/chem.201603206

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  7 in total

Review 1.  Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics.

Authors:  Maria Grazia Ferraro; Marialuisa Piccolo; Gabriella Misso; Rita Santamaria; Carlo Irace
Journal:  Pharmaceutics       Date:  2022-04-28       Impact factor: 6.525

2.  Highly Cytotoxic Osmium(II) Compounds and Their Ruthenium(II) Analogues Targeting Ovarian Carcinoma Cell Lines and Evading Cisplatin Resistance Mechanisms.

Authors:  Jana Hildebrandt; Norman Häfner; Daniel Kritsch; Helmar Görls; Matthias Dürst; Ingo B Runnebaum; Wolfgang Weigand
Journal:  Int J Mol Sci       Date:  2022-04-29       Impact factor: 6.208

3.  Binding mechanisms of half-sandwich Rh(III) and Ru(II) arene complexes on human serum albumin: a comparative study.

Authors:  Orsolya Dömötör; Éva A Enyedy
Journal:  J Biol Inorg Chem       Date:  2019-07-12       Impact factor: 3.358

4.  Investigations on the Anticancer Potential of Benzothiazole-Based Metallacycles.

Authors:  Stephan Mokesch; Klaudia Cseh; Heiko Geisler; Michaela Hejl; Matthias H M Klose; Alexander Roller; Samuel M Meier-Menches; Michael A Jakupec; Wolfgang Kandioller; Bernhard K Keppler
Journal:  Front Chem       Date:  2020-04-03       Impact factor: 5.221

Review 5.  Diversity in the Interaction of Amino Acid- and Peptide-Based Hydroxamic Acids with Some Platinum Group Metals in Solution.

Authors:  Linda Bíró; Péter Buglyó; Etelka Farkas
Journal:  Molecules       Date:  2022-01-20       Impact factor: 4.411

6.  The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo-A Comparison of O,O-, S,O-, and N,N-Chelate Effects.

Authors:  Iker Berasaluce; Klaudia Cseh; Alexander Roller; Michaela Hejl; Petra Heffeter; Walter Berger; Michael A Jakupec; Wolfgang Kandioller; Michael S Malarek; Bernhard K Keppler
Journal:  Chemistry       Date:  2019-11-19       Impact factor: 5.236

7.  Biological evaluation of novel thiomaltol-based organometallic complexes as topoisomerase IIα inhibitors.

Authors:  Maria S Legina; Juan J Nogueira; Wolfgang Kandioller; Michael A Jakupec; Leticia González; Bernhard K Keppler
Journal:  J Biol Inorg Chem       Date:  2020-03-19       Impact factor: 3.358

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.